OCULAR THERAPEUTIX, INC. has recently released its 10-Q report. Ocular Therapeutix is a Bedford, Massachusetts-based biopharmaceutical company focused on eye diseases, using a bioresorbable hydrogel platform to develop and commercialize ophthalmic therapies in the United States. Its commercial product is DEXTENZA, a dexamethasone insert for post-surgical ocular inflammation and pain and for allergic conjunctivitis, while its pipeline includes AXPAXLI for wet age-related macular degeneration and diabetic retinal disease, and OTX-TIC for open-angle glaucoma or ocular hypertension.
In Item 2, Management’s Discussion and Analysis, the company said the quarter should be read alongside its condensed consolidated financial statements, the related notes, and its annual report for the year ended December 31, 2025. It also said the discussion includes forward-looking statements tied to risks and uncertainties, and pointed readers to the risk factors in the 2025 annual report. The company described itself as an integrated biopharmaceutical company centered on AXPAXLI, its investigational intravitreal hydrogel incorporating axitinib, and said the program is in two Phase 3 registrational studies: SOL for wet AMD and HELIOS for diabetic retinal disease, including NPDR.
The most detailed development in the filing was the SOL-1 wet AMD trial. Ocular Therapeutix said the trial enrolled 344 subjects and that more than 100 sites in the United States and Argentina participated. The company reported that all subjects completed the Week 52 visit, retention remained above 95%, and more than 95% of rescue events reviewed under masking met protocol criteria. It said no safety signals were identified by the independent data and safety monitoring committee.
The company reported that AXPAXLI met the SOL-1 primary endpoint at Week 36, with 74.1% of subjects maintaining vision versus 55.8% for aflibercept 2 mg, a risk difference of 17.5% and a p-value of 0.0006. At Week 52, 65.9% of AXPAXLI subjects maintained vision versus 44.2% in the aflibercept arm, a risk difference of 21.1% and a p-value of less than 0.0001. Ocular Therapeutix said no treatment-related ocular or systemic serious adverse events were observed, and no cases of endophthalmitis, occlusive retinal vasculitis, non-occlusive retinal vasculitis, retinal detachment, or implant migration to the anterior chamber were seen in the AXPAXLI arm.
Safety data in the filing showed 49.4% of AXPAXLI subjects had at least one non-ocular adverse event versus 42.4% in the aflibercept group, while 52.9% had at least one ocular adverse event in the study eye versus 33.7% in the control arm. The most common ocular events in the AXPAXLI arm included vitreous floaters in 12.4% of subjects, cataract in 7.1%, conjunctival hemorrhage in 6.5%, retinal hemorrhage in 5.9%, dry eye in 4.1%, and vitreous detachment in 4.1%.
For the SOL-R wet AMD trial, the company said randomization was completed with 631 subjects, above the original 555-subject target. The study is testing AXPAXLI 450 µg dosed every 24 weeks against aflibercept 2 mg dosed every eight weeks, with a third aflibercept 8 mg arm included for masking. The primary endpoint is mean BCVA change from baseline at Week 56, and topline data are expected in the first quarter of 2027.
The filing also noted that DEXTENZA remains the company’s marketed product and that OTX-TIC has completed Phase 2 testing, with next steps still under evaluation. Ocular Therapeutix said it continues to work under a license agreement and collaboration with AffaMed Therapeutics Limited for DEXTENZA and OTX-TIC. Following these announcements, the company's shares moved -3.07%, and are now trading at a price of $9.47. If you want to know more, read the company's complete 10-Q report here.
